Michael Sheaff

7.2k total citations
98 papers, 2.7k citations indexed

About

Michael Sheaff is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Biotechnology. According to data from OpenAlex, Michael Sheaff has authored 98 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 24 papers in Molecular Biology and 19 papers in Biotechnology. Recurrent topics in Michael Sheaff's work include Occupational and environmental lung diseases (20 papers), Cancer Research and Treatments (19 papers) and Neuroblastoma Research and Treatments (9 papers). Michael Sheaff is often cited by papers focused on Occupational and environmental lung diseases (20 papers), Cancer Research and Treatments (19 papers) and Neuroblastoma Research and Treatments (9 papers). Michael Sheaff collaborates with scholars based in United Kingdom, United States and Ireland. Michael Sheaff's co-authors include Peter W. Szlosarek, Stavros N Georgiannos, Melissa Phillips, Jeremy Steele, Muhammad M. Yaqoob, A W Goode, Martin Raftery, Robin Rudd, Jo-Anne Chin Aleong and Edward Sharples and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Michael Sheaff

90 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Sheaff United Kingdom 28 891 600 541 426 407 98 2.7k
Galina Pizov Israel 25 812 0.9× 373 0.6× 766 1.4× 269 0.6× 605 1.5× 67 2.6k
Kenichi Ohashi Japan 29 939 1.1× 796 1.3× 1.3k 2.4× 399 0.9× 747 1.8× 300 4.1k
Freda Passam Australia 31 469 0.5× 592 1.0× 780 1.4× 297 0.7× 468 1.1× 97 3.2k
George Vaiopoulos Greece 30 605 0.7× 489 0.8× 631 1.2× 360 0.8× 360 0.9× 161 3.1k
Jean–Paul Duong Van Huyen France 39 487 0.5× 300 0.5× 767 1.4× 498 1.2× 1.8k 4.5× 108 4.7k
Hans Stricker United States 32 2.3k 2.6× 733 1.2× 1.7k 3.2× 224 0.5× 977 2.4× 104 4.1k
Grzegorz Dworacki Poland 23 221 0.2× 885 1.5× 765 1.4× 252 0.6× 221 0.5× 99 2.6k
Peter C. Harpel United States 25 431 0.5× 261 0.4× 599 1.1× 260 0.6× 530 1.3× 46 2.8k
Amy Powers United States 20 1.4k 1.5× 671 1.1× 687 1.3× 148 0.3× 168 0.4× 40 2.7k
D C Stump United States 33 716 0.8× 231 0.4× 287 0.5× 272 0.6× 784 1.9× 67 3.1k

Countries citing papers authored by Michael Sheaff

Since Specialization
Citations

This map shows the geographic impact of Michael Sheaff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Sheaff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Sheaff more than expected).

Fields of papers citing papers by Michael Sheaff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Sheaff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Sheaff. The network helps show where Michael Sheaff may publish in the future.

Co-authorship network of co-authors of Michael Sheaff

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Sheaff. A scholar is included among the top collaborators of Michael Sheaff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Sheaff. Michael Sheaff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fernando, Raymond, David M. Lowe, Ashutosh Wechalekar, et al.. (2024). Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab. Journal of Clinical Medicine. 13(14). 4109–4109.
2.
3.
Phillips, Melissa, Michael D. Allen, Essam Ghazaly, et al.. (2023). A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. Pharmacological Reports. 75(3). 570–584. 4 indexed citations
4.
Thom, Maria, Graham Warner, Michael Sheaff, et al.. (2022). Progressive hemispheric atrophy in HIV: A Rasmussen's‐like variant of CD8 encephalitis?. Neuropathology and Applied Neurobiology. 48(4). e12794–e12794. 3 indexed citations
5.
Busacca, Sara, Aarti Gaba, Michael Sheaff, et al.. (2022). BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. Oncogene. 42(8). 572–585. 12 indexed citations
6.
Szlosarek, Peter W., Akhila Wimalasingham, Melissa Phillips, et al.. (2021). Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer. Cancer Medicine. 10(19). 6642–6652. 14 indexed citations
7.
Busacca, Sara, Laura O’Regan, Annabel Sharkey, et al.. (2020). BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Molecular Cancer Therapeutics. 20(2). 379–388. 13 indexed citations
8.
Petrovic, Roseanna M., Daniela Achkova, Tomasz Zabinski, et al.. (2017). CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. OncoImmunology. 6(12). e1363137–e1363137. 52 indexed citations
9.
White, William E., Emma O’Lone, Michael Sheaff, & Muhammad M. Yaqoob. (2014). Graft pyelonephritis causing graft failure from de novo AA amyloid. Kidney International. 85(2). 481–481.
10.
Busacca, Sara, Astero Klabatsa, Ken Arthur, et al.. (2013). BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. PLoS ONE. 8(6). e65489–e65489. 13 indexed citations
11.
Savage, Kienan I., Jaine K. Blayney, Kathy Gately, et al.. (2011). PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer. The Journal of Pathology. 224(4). 564–574. 29 indexed citations
12.
13.
Harwood, Catherine, Charlotte M. Proby, Jane McGregor, et al.. (2006). Clinicopathologic features of skin cancer in organ transplant recipients: A retrospective case-control series. Journal of the American Academy of Dermatology. 54(2). 290–300. 104 indexed citations
14.
Fennell, Dean A., Jeremy Steele, Jonathan Shamash, et al.. (2006). Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 109(1). 93–99. 37 indexed citations
15.
Rajakariar, Ravindra, et al.. (2005). High Pre‐Transplant Soluble CD30 Levels are Predictive of the Grade of Rejection. American Journal of Transplantation. 5(8). 1922–1925. 53 indexed citations
16.
Sharples, Edward, Nimesh S. A. Patel, Hélder Mota‐Filipe, et al.. (2004). Erythropoietin Protects the Kidney against the Injury and Dysfunction Caused by Ischemia-Reperfusion. Journal of the American Society of Nephrology. 15(8). 2115–2124. 331 indexed citations
17.
Sheaff, Michael, et al.. (2002). Extramedullary Hematopoiesis in the Endometrium. International Journal of Gynecological Pathology. 21(2). 178–181. 17 indexed citations
18.
El‐Rifai, Wael, Dia Kamel, Marcelo L. Larramendy, et al.. (2000). DNA Copy Number Changes in Schistosoma-Associated and Non-Schistosoma-Associated Bladder Cancer. American Journal Of Pathology. 156(3). 871–878. 34 indexed citations
19.
Sheaff, Michael. (1998). Principles And Practice Of Surgical Pathology And Cytopathology.. Journal of Clinical Pathology. 51(6). 487–488. 59 indexed citations
20.
Mahalingasivam, Viyaasan, J. B. Booth, Michael Sheaff, & Magdi Yaqoob. (1969). Nephrotic syndrome in adults.. BMJ. 2(5656). 529–530. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Galina Pizov Breakdown of academic impact, for papers by Kenichi Ohashi Breakdown of academic impact, for papers by Freda Passam Breakdown of academic impact, for papers by George Vaiopoulos Breakdown of academic impact, for papers by Jean–Paul Duong Van Huyen Breakdown of academic impact, for papers by Hans Stricker Breakdown of academic impact, for papers by Grzegorz Dworacki Breakdown of academic impact, for papers by Peter C. Harpel Breakdown of academic impact, for papers by Amy Powers Breakdown of academic impact, for papers by D C Stump
Rankless by CCL
2026